| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802931401035 | 293140103 | CLOPIDOGREL APOTEX F.C.TAB 75MG/TAB BTx 28 σε BLISTERS (PVC/PE/PVDC/ALU) (PVC/PE/PVDC/ALU) | 6.72 | 07.05 | 9.72 |
| 05/2018 | 2803024501038 | 302450103 | CLOPIDOGREL ZENTIVA F.C.TAB 75MG/TAB BTx28 δισκία σε BLISTERS (PVC/PVDC) BLISTERS (PVC/PVDC) | 2.42 | 2.54 | 3.50 |
| 05/2018 | 2802927301035 | 292730103 | CLOPIDOGREL TAD F.C.TAB 75MG/TAB BTx 28 σε BLISTERS (OPA/AL/PVC/AL) (OPA/AL/PVC/AL) | 6.72 | 07.05 | 9.72 |
For the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease
The active metabolite of clopidogrel prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. he drug specifically and irreversibly inhibits the P2Y12 subtype of ADP receptor, which is important in aggregation of platelets and cross-linking by the protein fibrin. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of clopidogrel.
Symptoms of acute toxicity include vomiting (in baboons), prostration, difficult breathing, and gastrointestinal hemorrhage.
Absorption is at least 50% based on urinary excretion of clopidogrel-related metabolites. Bioavailability has not been found to be affected by food.
Carboxylic acid derivative: 8 hours (after single and multiple doses). Covalent binding to platelets has accounted for 2% of radiolabeled clopidogrel with a half-life of 11 days.
Following an oral dose of 14C-labeled clopidogrel in humans, approximately 50% of total radioactivity was excreted in urine and approximately 46% in feces over the 5 days post-dosing.